The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.
An article from
IPO window
The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.
Published Aug. 5, 2026
Getty Images
Attovia Therapeutics (ATTO) raises upsized IPO on Nasdaq, extending biotech's 3-week streak. CEO Tao Fu's firm targets I&I with…
Attovia files for a Nasdaq IPO under ticker ATTO, becoming the third biotech to file this month after Scribe and Apnimed.
The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s…
After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech…
The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted…
Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most…
